(VIANEWS) – Evercore Partners (EVR), Neurocrine Biosciences (NBIX), ANI Pharmaceuticals (ANIP) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Evercore Partners (EVR)
26.5% sales growth and 16.26% return on equity
Evercore Inc., together with its subsidiaries, operates as an independent investment banking advisory firm in the United States, Europe, Latin America, and internationally. It operates through two segments, Investment Banking and Investment Management. The Investment Banking segment offers strategic advisory services, such as mergers and acquisitions, strategic, defense, and shareholder advisory, special committee assignments, and transaction structuring; Capital Markets Advisory, including equity capital markets, restructuring, debt advisory, private placement advisory, market risk management and hedging, private capital advisory, and private funds; and research, sales, and trading professionals services on a content-led platform to its institutional investor clients. The Investment Management segment provides wealth management services to high-net-worth individuals, foundations, and endowments; and manages financial assets for institutional investors. The company was formerly known as Evercore Partners Inc. and changed its name to Evercore Inc. in August 2017. Evercore Inc. was founded in 1995 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Evercore Partners has a trailing twelve months EPS of $6.36.
PE Ratio
Evercore Partners has a trailing twelve months price to earnings ratio of 30.01. Meaning, the purchaser of the share is investing $30.01 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.26%.
2. Neurocrine Biosciences (NBIX)
22.1% sales growth and 12.68% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $2.47.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 57.26. Meaning, the purchaser of the share is investing $57.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.68%.
Yearly Top and Bottom Value
Neurocrine Biosciences’s stock is valued at $141.43 at 01:22 EST, below its 52-week high of $148.37 and way above its 52-week low of $89.04.
3. ANI Pharmaceuticals (ANIP)
13% sales growth and 4.72% return on equity
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Earnings Per Share
As for profitability, ANI Pharmaceuticals has a trailing twelve months EPS of $0.85.
PE Ratio
ANI Pharmaceuticals has a trailing twelve months price to earnings ratio of 79.52. Meaning, the purchaser of the share is investing $79.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.72%.
Previous days news about ANI Pharmaceuticals(ANIP)
- According to Zacks on Tuesday, 9 April, "Some better-ranked stocks in the overall healthcare sector include ADMA Biologics (ADMA Quick QuoteADMA – Free Report) , ANI Pharmaceuticals (ANIP Quick QuoteANIP – Free Report) and Ligand Pharmaceuticals (LGND Quick QuoteLGND – Free Report) ,each sporting a Zacks Rank #1 (Strong Buy) at present. ", "Earnings of ANI Pharmaceuticals beat estimates in each of the last four quarters. "
4. Radcom Ltd. (RDCM)
12.2% sales growth and 4.78% return on equity
RADCOM Ltd. provides 5G ready cloud-native network intelligence and service assurance solutions for telecom operators or communication service providers (CSPs). It offers RADCOM ACE, including RADCOM Service Assurance, a cloud-native, 5G-ready, and virtualized service assurance solutions, which allows telecom operators to gain end-to-end network visibility and customer experience insights across all networks; RADCOM Network Visibility, a cloud-native network packet broker and filtering solution that allows CSPs to manage network traffic at scale across multiple cloud environments, and control the visibility layer to perform analysis of select datasets; and RADCOM Network Insights, a business intelligence solution that offers insights for multiple use cases enabled by data captured and correlated through RADCOM Network Visibility and RADCOM Service Assurance. The company also provides solutions for mobile and fixed networks, such as 5G, long term evolution, voice over LTE, voice over Wifi, IP multimedia subsystem, voice over IP, and universal mobile telecommunication service. It sells its products directly, as well as through a network of distributors and resellers in North America, Asia, Latin America, Europe, the Middle East, and Africa. The company was formerly known as Big Blue Catalogue Ltd. and changed its name to RADCOM Ltd. in 1989. RADCOM Ltd. was incorporated in 1985 and is headquartered in Tel Aviv, Israel.
Earnings Per Share
As for profitability, Radcom Ltd. has a trailing twelve months EPS of $0.24.
PE Ratio
Radcom Ltd. has a trailing twelve months price to earnings ratio of 45.83. Meaning, the purchaser of the share is investing $45.83 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.78%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14%, now sitting on 51.6M for the twelve trailing months.
Moving Average
Radcom Ltd.’s value is way above its 50-day moving average of $9.99 and way above its 200-day moving average of $9.03.
5. Grupo Aeroportuario del Centro Norte S.A.B. de C.V. (OMAB)
11.8% sales growth and 54.59% return on equity
Grupo Aeroportuario del Centro Norte, S.A.B. de C.V., together with its subsidiaries, holds concessions to develop, operate, and maintain airports in Mexico. The company operates 13 international airports in Monterrey, Acapulco, Mazatlán, Zihuatanejo, Ciudad Juárez, Reynosa, Chihuahua, Culiacán, Durango, San Luis Potosí, Tampico, Torreón, and Zacatecas cities. It also operates the NH Collection Hotel in Terminal 2 of the Mexico City International Airport; and a hotel under the Hilton Garden Inn name at the Monterrey International Airport. In addition, the company provides aeronautical services, which include passenger, aircraft landing and parking, boarding and unloading, passenger walkway, and airport security services. Further, it offers complementary services that comprise leasing of space to airlines, cargo handling, baggage-screening, permanent and non-permanent ground transportation, and access rights services; non-aeronautical services, such as leasing of space at its airports to retailers, restaurants, and other commercial tenants, as well as maintaining of parking facilities and advertising; and diversification services, which consists of operation and lease of the industrial park and real estate services, as well as hotel and air cargo logistics services. Additionally, the company provides construction services. It has a strategic alliance with VYNMSA Desarrollo Inmobiliario, S.A. de C.V. to build and operate an industrial park at the Monterrey airport. The company was founded in 1998 and is headquartered in Mexico City, Mexico.
Earnings Per Share
As for profitability, Grupo Aeroportuario del Centro Norte S.A.B. de C.V. has a trailing twelve months EPS of $5.25.
PE Ratio
Grupo Aeroportuario del Centro Norte S.A.B. de C.V. has a trailing twelve months price to earnings ratio of 14.32. Meaning, the purchaser of the share is investing $14.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 54.59%.
Moving Average
Grupo Aeroportuario del Centro Norte S.A.B. de C.V.’s value is above its 50-day moving average of $71.86 and below its 200-day moving average of $78.78.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 22.7% and a drop 4.2% for the next.
Sales Growth
Grupo Aeroportuario del Centro Norte S.A.B. de C.V.’s sales growth is 1% for the ongoing quarter and 11.8% for the next.
6. Broadridge Financial Solutions (BR)
7% sales growth and 35.48% return on equity
Broadridge Financial Solutions, Inc. provides investor communications and technology-driven solutions for the financial services industry. The company's Investor Communication Solutions segment processes and distributes proxy materials to investors in equity securities and mutual funds, as well as facilitates related vote processing services; and distributes regulatory reports, class action, and corporate action/reorganization event information, as well as tax reporting solutions. It also offers ProxyEdge, an electronic proxy delivery and voting solution; data-driven solutions and an end-to-end platform for content management, composition, and omni-channel distribution of regulatory, marketing, and transactional information, as well as mutual fund trade processing services; solutions for public corporations and mutual funds; data and analytics solutions; SEC filing and capital markets transaction services; registrar, stock transfer, and record-keeping services; and omni-channel customer communications solutions, as well as operates Broadridge Communications Cloud platform that creates, delivers, and manages communications and customer engagement activities. Its Global Technology and Operations segment provides solutions that automate the front-to-back transaction lifecycle of equity, mutual fund, fixed income, foreign exchange and exchange-traded derivatives, order capture and execution, trade confirmation, margin, cash management, clearing and settlement, reference data management, reconciliations, securities financing and collateral management, asset servicing, compliance and regulatory reporting, portfolio accounting, and custody-related services. This segment also offers business process outsourcing services; technology solutions, such portfolio management, compliance, fee billing, and operational support solutions; and capital market and wealth and investment management solutions. The company was founded in 1962 and is headquartered in Lake Success, New York.
Earnings Per Share
As for profitability, Broadridge Financial Solutions has a trailing twelve months EPS of $5.75.
PE Ratio
Broadridge Financial Solutions has a trailing twelve months price to earnings ratio of 34.91. Meaning, the purchaser of the share is investing $34.91 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.48%.
Sales Growth
Broadridge Financial Solutions’s sales growth for the next quarter is 7%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.7%, now sitting on 6.32B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 9.3% and 9.3%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Broadridge Financial Solutions’s EBITDA is 4.36.
